FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3104390849> ?p ?o ?g. }

• W3104390849 abstract "Background SQZ-PBMC-HPV is a therapeutic cancer vaccine created with Cell Squeeze®, a proprietary cell-engineering system. SQZ-PBMC-HPV is a novel cancer vaccine generated from peripheral blood mononuclear cells (PBMC) squeezed with HPV16 E6 and E7 antigens, resulting in delivery into the cytosol. The resulting antigen presenting cells (APCs) provide enhanced antigen presentation on MHC-I to potentially elicit robust, antigen-specific CD8+ T cell responses. Importantly, SQZ-PBMC-HPV are neither genetically modified nor immune effector cells.Studies in MHC-I knockout mice demonstrated that activation of antigen specific CD8+ tumor infiltrating lymphocytes (TILs) was a direct effect of cytosolic antigen delivery to PBMCs. In the murine TC-1 tumor model, tumor regression correlated with an influx of HPV16-specific CD8+ TILs. In vitro studies with human volunteer PBMCs demonstrated that each subset is capable of inducing CD8+ T cell responses. The Phase 1 study includes a significant biomarker program to investigate whether pharmacodynamic effects observed in non-clinical studies correlate with potential clinical benefit. Immunogenic and pharmacodynamic endpoints include Elispot assays to measure frequency of interferon gamma secreting cells, as well as quantification and characterization of TILs and tumor microenvironment. In addition, various cytokine responses and circulating cell-free HPV16 DNA levels in plasma are measured. Methods SQZ-PBMC-HPV-101 ( NCT04084951 ) is open for enrollment to HLA A*02+ patients with HPV16+ recurrent, locally advanced or metastatic solid tumors and includes escalation cohorts for monotherapy and in combination with atezolizumab. After initial demonstration of safety, the study assesses dose effect by testing different cell dose levels, the effect of prolonged antigen priming in Cycle 1 [APC administration on Day 1 only compared to Days 1 and 2 (double priming)] and the impact of treatment duration to identify the optimal dose regimen. The cycle length is 3 weeks, and patients will receive SQZ-PBMC-HPV for up to 1 year or until available autologous drug product is exhausted. Atezolizumab will be administered for up to 1 year. Eligible patients including but not limited to anal, cervical and head and neck tumors will undergo a single leukapheresis at the study site. The manufacturing process includes a maturation step and takes less than 24 hours. The vein-to-vein time for the 1st administration is approximately one week. Patients must have a lesion that can be biopsied with acceptable clinical risk and agree to have a fresh biopsy at Screening and on study. A Study Safety Committee is in place. No formal statistical hypothesis testing will be performed. Results N/A Conclusions N/A Trial Registration NCT04084951 Ethics Approval The study is registered on clinicaltrials.gov was approved by the Ethics Board of all institution listed as recruiting." @default.
• W3104390849 created "2020-11-23" @default.
• W3104390849 creator A5007992309 @default.
• W3104390849 creator A5009132832 @default.
• W3104390849 creator A5033482846 @default.
• W3104390849 creator A5038291054 @default.
• W3104390849 creator A5057925246 @default.
• W3104390849 creator A5058249824 @default.
• W3104390849 creator A5065202186 @default.
• W3104390849 creator A5069690249 @default.
• W3104390849 creator A5071800834 @default.
• W3104390849 creator A5082579643 @default.
• W3104390849 date "2020-11-01" @default.
• W3104390849 modified "2023-10-18" @default.
• W3104390849 title "418 A phase 1, dose escalation and dose expansion study of SQZ PBMC HPV as monotherapy and in combination with atezolizumab in HLA-A*02+ Patients with HPV16+ recurrent, or metastatic solid tumors" @default.
• W3104390849 doi "https://doi.org/10.1136/jitc-2020-sitc2020.0418" @default.
• W3104390849 hasPublicationYear "2020" @default.
• W3104390849 type Work @default.
• W3104390849 sameAs 3104390849 @default.
• W3104390849 citedByCount "0" @default.
• W3104390849 crossrefType "journal-article" @default.
• W3104390849 hasAuthorship W3104390849A5007992309 @default.
• W3104390849 hasAuthorship W3104390849A5009132832 @default.
• W3104390849 hasAuthorship W3104390849A5033482846 @default.
• W3104390849 hasAuthorship W3104390849A5038291054 @default.
• W3104390849 hasAuthorship W3104390849A5057925246 @default.
• W3104390849 hasAuthorship W3104390849A5058249824 @default.
• W3104390849 hasAuthorship W3104390849A5065202186 @default.
• W3104390849 hasAuthorship W3104390849A5069690249 @default.
• W3104390849 hasAuthorship W3104390849A5071800834 @default.
• W3104390849 hasAuthorship W3104390849A5082579643 @default.
• W3104390849 hasConcept C137061746 @default.
• W3104390849 hasConcept C147483822 @default.
• W3104390849 hasConcept C154317977 @default.
• W3104390849 hasConcept C167672396 @default.
• W3104390849 hasConcept C202751555 @default.
• W3104390849 hasConcept C203014093 @default.
• W3104390849 hasConcept C2775949291 @default.
• W3104390849 hasConcept C2776090121 @default.
• W3104390849 hasConcept C2776107976 @default.
• W3104390849 hasConcept C2777701055 @default.
• W3104390849 hasConcept C2779053233 @default.
• W3104390849 hasConcept C2780030458 @default.
• W3104390849 hasConcept C502942594 @default.
• W3104390849 hasConcept C55493867 @default.
• W3104390849 hasConcept C71924100 @default.
• W3104390849 hasConcept C86803240 @default.
• W3104390849 hasConcept C8891405 @default.
• W3104390849 hasConceptScore W3104390849C137061746 @default.
• W3104390849 hasConceptScore W3104390849C147483822 @default.
• W3104390849 hasConceptScore W3104390849C154317977 @default.
• W3104390849 hasConceptScore W3104390849C167672396 @default.
• W3104390849 hasConceptScore W3104390849C202751555 @default.
• W3104390849 hasConceptScore W3104390849C203014093 @default.
• W3104390849 hasConceptScore W3104390849C2775949291 @default.
• W3104390849 hasConceptScore W3104390849C2776090121 @default.
• W3104390849 hasConceptScore W3104390849C2776107976 @default.
• W3104390849 hasConceptScore W3104390849C2777701055 @default.
• W3104390849 hasConceptScore W3104390849C2779053233 @default.
• W3104390849 hasConceptScore W3104390849C2780030458 @default.
• W3104390849 hasConceptScore W3104390849C502942594 @default.
• W3104390849 hasConceptScore W3104390849C55493867 @default.
• W3104390849 hasConceptScore W3104390849C71924100 @default.
• W3104390849 hasConceptScore W3104390849C86803240 @default.
• W3104390849 hasConceptScore W3104390849C8891405 @default.
• W3104390849 hasLocation W31043908491 @default.
• W3104390849 hasOpenAccess W3104390849 @default.
• W3104390849 hasPrimaryLocation W31043908491 @default.
• W3104390849 hasRelatedWork W12714210 @default.
• W3104390849 hasRelatedWork W15718139 @default.
• W3104390849 hasRelatedWork W16473764 @default.
• W3104390849 hasRelatedWork W19818330 @default.
• W3104390849 hasRelatedWork W20203410 @default.
• W3104390849 hasRelatedWork W2151330 @default.
• W3104390849 hasRelatedWork W2773312 @default.
• W3104390849 hasRelatedWork W4041773 @default.
• W3104390849 hasRelatedWork W6417289 @default.
• W3104390849 hasRelatedWork W8453341 @default.
• W3104390849 isParatext "false" @default.
• W3104390849 isRetracted "false" @default.
• W3104390849 magId "3104390849" @default.
• W3104390849 workType "article" @default.